OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 150 filers reported holding OCULAR THERAPEUTIX INC in Q2 2021. The put-call ratio across all filers is 0.38 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $189,543 | -85.7% | 60,364 | -76.5% | 0.00% | – |
Q2 2023 | $1,327,503 | +115.2% | 257,268 | +119.8% | 0.00% | – |
Q1 2023 | $616,832 | +694.7% | 117,046 | +323.7% | 0.00% | – |
Q4 2022 | $77,620 | -17.4% | 27,623 | +21.9% | 0.00% | – |
Q3 2022 | $94,000 | -50.3% | 22,658 | -51.7% | 0.00% | – |
Q2 2022 | $189,000 | -59.4% | 46,944 | -29.5% | 0.00% | – |
Q4 2021 | $465,000 | -68.3% | 66,575 | -54.6% | 0.00% | – |
Q3 2021 | $1,465,000 | -35.2% | 146,557 | -8.1% | 0.00% | – |
Q2 2021 | $2,260,000 | +233.8% | 159,395 | +286.4% | 0.00% | – |
Q1 2021 | $677,000 | -37.9% | 41,246 | -21.7% | 0.00% | – |
Q4 2020 | $1,090,000 | +376.0% | 52,653 | +74.8% | 0.00% | – |
Q3 2020 | $229,000 | -79.3% | 30,126 | -77.3% | 0.00% | -100.0% |
Q2 2020 | $1,107,000 | +412.5% | 132,900 | +205.0% | 0.00% | – |
Q1 2020 | $216,000 | +137.4% | 43,579 | +223.1% | 0.00% | – |
Q2 2018 | $91,000 | – | 13,489 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |